Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: The inseparable twins

Cell Biology and Toxicology

Volumn 23, Issue 4, 2007, Pages 293-302

  Dumotier, B M ^a   Georgieva, A V ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adverse effects; Cardiac ventricle; Computerized models; Electrophysiology; Ion channels; Torsade de pointes

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL L TYPE; NEUROLEPTIC AGENT; PENTAMIDINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

CAPACITANCE BLOOD VESSEL; CELL STRAIN HEK293; CHO CELL; CONFERENCE PAPER; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; GENE MUTATION; HUMAN; IC 50; MATHEMATICAL MODEL; METHODOLOGY; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TACHYCARDIA; TORSADE DES POINTES;

ANIMAL TESTING ALTERNATIVES; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; HUMANS; LONG QT SYNDROME; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; TORSADES DE POINTES; XENOBIOTICS;

ANIMALIA;

EID: 33947540277     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-006-0882-6     Document Type: Conference Paper

References (41)

1. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm. 2005;2: S9-S15.
2. Antzelevich C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by early afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and Torsade de Pointes. J Am Coll Cardiol. 1994;23:259-77.
3. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-10.
4. Belardinelli L, Antzelevitch C, Vos M. Assessing predictors of drug-induced torsade de pointes [Review]. Trends Pharmacol Sci. 2003;24:619-25.
5. Belardinelli L, Shryock JC, Wu L, Song Y. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm. 2005;2(Suppl): S16-22.
6. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham D. Risk factors for prolonged QTc among US adults: third national health and nutrition examination survey. Eur J Cardiovasc Prev Rehabil. 2005;12:363-8.
7. Bottino D, Penland RC, Stamps A, et al. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol. 2006;90:414-43.
8. Cordes JS, Sun Z, Lloyd DB, et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol. 2005;145:15-23.
9. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
10. Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham DC. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 1994;105:389-95.
11. Fossa AA, Gorczyca W, Wisialowski T, et al. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods. 2006. [In press].
12. Garny A, Noble D, Kohl P. Dimensionality in cardiac modeling. Prog Biophys Mol Biol. 2005;87:47-66.
13. 2+ release. Biophys J. 2002;83:2918-45.
14. Habbab MA, el-Sherif N. TU alternans, long QTU, and torsade de pointes: clinical and experimental observations. Pacing Clin Electrophysiol. 1992;15:916-31.
15. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952;117:500-44.
16. Hunter PJ, Nielsen PM, Smaill BH, LeCrice IJ, Hunter IW. An anatomical heart model with applications to myocardial activation and ventricular mechanics. Crit Rev Biomed Eng. 1992;20:401-26.
17. Katchman AK, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006;316:1098-106.
18. Kusano KF, Hata Y, Yumoto A, Emori T, Sato T, Ohe T. Torsade de pointes with a normal QT interval associated with hypokalemia. Jpn Circ J. 2001;65:757-60.
19. Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Nonclinical proarrhythmia models: predicting torsades de pointes. J Pharmacol Toxicol Methods. 2005;52:46-59.
20. Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential, I: simulations of ionic currents and concentration changes. Circ Res. 1994a;74:1071-96.
21. Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential, II: afterdepolarizations, triggered activity, and potentiation. Circ Res. 1994b;74:1097-113.
22. McCulloch A, Bassingthwaighte J, Hunter P, Noble D. Computational biology of the heart: from structure to heart. Prog Biophys Mol Biol. 1998;69:153-5.
23. Mendes P, Kell D. Non-linear optimization of biochemical pathways: applications to metabolic engineering and parameter estimation. Bioinformatics. 1998;14:869-83.
24. Noble D. Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations. Nature. 1960;188:495-7.
25. Noda T, Shimizu W, Satomi K, et al. Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. Eur Heart J. 2004;25:2149-54.
26. Passier R, Denning C, Mummery C. Cardiomyocytes from human embryonic stem cells. Handb Exp Pharmacol. 2006;174:101-2.
27. Pearlstein RA, Vaz RJ, Kang J, Chen XL, et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003;13:1829-35.
28. + channel blockade: current knowledge and strategies for the early detection during drug development: Med Res Rev. 2005;25:133-66.
29. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
30. Restivo M, Caref EB, Kozhevnikov DO, El-Sherif N. Spatial dispersion of repolarization is a key factor in the arrhythmogenicity of long QT syndrome. J Cardiovasc Electrophysiol. 2004;15:323-31.
31. Roden D. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259:59-69.
32. Sanguinetti M, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463-9.
33. Satin J, Kehat I, Caspi O, et al. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol. 2004;559:479-96.
34. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol. 2004;142:1300-8.
35. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2005;2:758-72.
36. Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia: a mechanistic investigation of action potential conduction and conduction failure. Circ Res. 1997;80:124-38.
37. Ten Tusscher KH, Panfilov A. Alternans and spiral breakup in a human ventricular tissue model. Am J Physiol Heart Circ Physiol. 2006;291(3):H1088- 100.
38. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-7. [Erratum in: Science. 1998;282:1827].
39. Tsuji Y, Zicha S, Qi XY, Kodama I, Nattel S. Potassium channel subunit remodeling in rabbits exposed to long-term bradycardia or tachycardia: discrete arrhythmogenic consequences related to differential delayed-rectifier changes. Circulation. 2006;113:345-55.
40. Trayanova N, Aguel F, Larson C, Haro C. Modeling cardiac defibrillation: an inquiry in post-shock dynamics. In: Zipes DP and Jalife J. eds. Cardiac electrophysiology: from cell to bedside. 4th ed. Philadelphia: WB Saunders; 2004:282-90.
41. Zhou Z, Gong Q, Ye B, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J. 1998;74:230-41.